| Not Yet Recruiting | A Phase 2 Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine NCT07205796 | Shenzhen Shenxin Biotechnology Co., Ltd | Phase 2 |
| Not Yet Recruiting | Safety and Immunogenicity of CVI-VZV-001 in Adults Aged 50 Years and Above NCT07481604 | CHA Vaccine Institute Co., Ltd. | Phase 2 |
| Not Yet Recruiting | A Study to Evaluate the Effect of Recombinant Zoster Vaccine on New Diagnosis of Dementia in an Older Adult Po NCT07502560 | GlaxoSmithKline | Phase 4 |
| Not Yet Recruiting | Immunogenicity and Safety of SYS6017 in the Participants Aged 40 Years and Above NCT07354659 | CSPC Megalith Biopharmaceutical Co.,Ltd. | Phase 2 |
| Recruiting | Study to Evaluate the Safety and Immunogenicity of a Lyophilized Herpes Zoster Virus mRNA Vaccine NCT07400003 | Sinovac Biotech Co., Ltd | Phase 1 / Phase 2 |
| Recruiting | The Analgesic Efficacy and Safety of Tulodesvenlafaxine in Patients With Herpes Zoster NCT07370389 | Beijing Tiantan Hospital | N/A |
| Recruiting | The Analgesic Efficacy and Safety of Loxoprofen Sodium Patch in Patients With Herpes Zoster NCT07378059 | Beijing Tiantan Hospital | N/A |
| Recruiting | The Analgesic Efficacy and Safety of Desvenlafaxine in Patients With Herpes Zoster NCT07361809 | Beijing Tiantan Hospital | N/A |
| Recruiting | The Analgesic Efficacy and Safety of Crisugabalin in Patients With Herpes Zoster NCT07307976 | Beijing Tiantan Hospital | N/A |
| Recruiting | The Analgesic Efficacy and Safety of Flurbiprofen Patch in Patients With Herpes Zoster NCT07370402 | Beijing Tiantan Hospital | N/A |
| Recruiting | The Analgesic Efficacy and Safety of Venlafaxine for Prevention of Postherpetic Neuralgia in Patients With Acu NCT07361796 | Beijing Tiantan Hospital | N/A |
| Recruiting | The Analgesic Efficacy and Safety of Mirogabalin in Patients With Herpes Zoster NCT07307170 | Beijing Tiantan Hospital | N/A |
| Active Not Recruiting | A Phase III Clinical Trial to Evaluate Long-Term Protective Efficacy of Recombinant Zoster Vaccine (CHO Cell) NCT07293065 | MAXVAX Biotechnology Limited Liability Company | Phase 3 |
| Recruiting | The Analgesic Efficacy and Safety of Baclofen in Patients With Herpes Zoster NCT07378046 | Beijing Tiantan Hospital | N/A |
| Recruiting | Efficacy and Safety of Brivudine in the Treatment of Herpes Zoster NCT07099157 | Peking University Third Hospital | Phase 4 |
| Active Not Recruiting | Clinical Efficacy and Safety of Tender Point Infiltration (TPI) for Acute and Subacute Zoster Associated Pain NCT06344403 | Beijing Tiantan Hospital | N/A |
| Recruiting | Erector Spinae Plane Block Versus Transcutaneous Radiofrequency in Postherpetic Neuralgia NCT07400640 | Diskapi Teaching and Research Hospital | — |
| Not Yet Recruiting | Safety and Immunogenicity of SYS6017 in Healthy Participants Aged 40 Years or More NCT06954818 | CSPC Megalith Biopharmaceutical Co.,Ltd. | Phase 1 |
| Not Yet Recruiting | Esketamine Combined With PRF of DRG for Acute/Subacute Zoster-associated Pain NCT06914206 | Beijing Tiantan Hospital | N/A |
| Not Yet Recruiting | Subcutaneous Lidocaine Injection in Acute Herpes Zoster Neuralgia and Post-herpetic Neuralgia NCT06882525 | Ankara City Hospital Bilkent | N/A |
| Active Not Recruiting | Clinical Trial of Recombinant Herpes Zoster Vaccine (CHO Cell) in Healthy Chinese Population Aged 40 Years and NCT06851832 | Ab&B Bio-tech Co., Ltd.JS | Phase 1 / Phase 2 |
| Not Yet Recruiting | A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Recombinant Herpes Zoster Vaccine NCT06801509 | Sinocelltech Ltd. | Phase 1 / Phase 2 |
| Not Yet Recruiting | Shingrix in Patients With Rheumatic Diseases: a Double-blind Placebo-controlled RCT NCT04748939 | Tuen Mun Hospital | Phase 4 |
| Not Yet Recruiting | Phase III Clinical Trial of Lot-to-lot Consistency of Recombinant Herpes Zoster Vaccine (CHO Cell). NCT06654700 | MAXVAX Biotechnology Limited Liability Company | Phase 3 |
| Recruiting | Electroacupuncture Regulation of Immune Cells in Herpes Zoster NCT06643247 | First People's Hospital of Hangzhou | N/A |
| Not Yet Recruiting | Impact on Quality of Life and Burden of Disease in Adults With Herpes Zoster NCT06667245 | Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz | — |
| Active Not Recruiting | Clinical Trial to Evaluate EuHZV in Healthy Adults Aged 50 to 69 Years NCT06409494 | EuBiologics Co.,Ltd | Phase 1 |
| Active Not Recruiting | Efficacy, Safety and Immunogenicity Study of Recombinant Zoster Vaccine(CHO Cell) in Adults Aged 40 Years and NCT06447779 | MAXVAX Biotechnology Limited Liability Company | Phase 3 |
| Completed | A Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) NCT06375512 | Shenzhen Shenxin Biotechnology Co., Ltd | Phase 1 |
| Recruiting | Risk Factors of Anxiety and Depression in Patients With Herpes Zoster Neuralgia NCT06449547 | Huazhong University of Science and Technology | — |
| Recruiting | Safety and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Health NCT06569823 | Dynavax Technologies Corporation | Phase 1 / Phase 2 |
| Active Not Recruiting | A Safety and Immunogenicity Trial of the Recombinant Zoster Vaccine （CHO Cell）, LYB004 in Adults Aged 50 to 70 NCT06335849 | Guangzhou Patronus Biotech Co., Ltd. | Phase 1 |
| Unknown | Evaluation of Herpes Zoster Characteristics and Costs in Cancer Population. NCT06207487 | AC Camargo Cancer Center | — |
| Completed | A Study to Evaluate the Safety and Immunogenicity of ChAdOx1-VZV in Healthy Adults Aged 50-65 Years NCT05991427 | CanSino Biologics Inc. | Phase 1 |
| Unknown | Herpes Zoster Hospitalizations in Italy NCT05952271 | University of L'Aquila | — |
| Recruiting | A Phase Ⅲ Clinical Study to Evaluate Protective Efficacy and Safety of a Recombinant Herpes Zoster Vaccine NCT06088745 | Beijing Luzhu Biotechnology Co., Ltd. | Phase 3 |
| Unknown | Phase I Clinical Trial of a Candidate Herpes Zoster Vaccine NCT05718037 | Wuhan BravoVax Co., Ltd. | Phase 1 |
| Active Not Recruiting | Immunogenicity and Safety of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 30 Years a NCT05856084 | MAXVAX Biotechnology Limited Liability Company | Phase 2 |
| Unknown | Non-inferiority Study of ZK-A03 in Treatment of Herpes Zoster Before and After the Alteration of the Active In NCT05806918 | Lee's Pharmaceutical Limited | Phase 3 |
| Unknown | A Study to Evaluate Safety and Tolerability of a Recombinant Herpes Zoster Vaccine NCT05750017 | Beijing Luzhu Biotechnology Co., Ltd. | Phase 1 |
| Recruiting | Safety and Immunogenicity of CVI-VZV-001 for Prevention of Herpes Zoster in Healthy Adults Age 50 Years and Ab NCT06137755 | CHA Vaccine Institute Co., Ltd. | Phase 1 |
| Recruiting | Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Coun NCT05580458 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 / Phase 2 |
| Completed | The Safety and Immunogenicity Study of the Recombinant Zoster Vaccine (CHO Cell) NCT05769049 | Jiangsu Rec-Biotechnology Co., Ltd. | Phase 1 |
| Active Not Recruiting | A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥50 Years of NCT05701800 | ModernaTX, Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | Safety and Immunogenicity of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 18 Years a NCT05636436 | MAXVAX Biotechnology Limited Liability Company | Phase 1 |
| Completed | A Study Exploring Efficacy of Peginterferon in Patients With Herpes Zoster NCT05492591 | Shanghai Institute Of Biological Products | Phase 2 |
| Active Not Recruiting | A Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoste NCT05371080 | GlaxoSmithKline | Phase 3 |
| Unknown | The Efficacy and Safety of Intradermal Acupuncture for Acute Herpes Zoster NCT05348382 | The Third Affiliated hospital of Zhejiang Chinese Medical University | N/A |
| Completed | Multidisciplinary Hospital-Territory Vaccine Center: a Model for Achieving the Herpes Zoster Vaccine Coverage NCT06334861 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | — |
| Active Not Recruiting | Safety of Herpes Zoster Subunit (HZ/su) Vaccine During Pregnancy in Adult Women With Immunocompromised Conditi NCT05811754 | GlaxoSmithKline | — |
| Completed | A Study on the Immune Response and Safety of a Vaccine Against Herpes Zoster in Adults Aged 50 Years and Older NCT05219253 | GlaxoSmithKline | Phase 3 |
| Active Not Recruiting | Safety and Immunogenicity of CRV-101 Vaccine for the Prevention of Herpes Zoster in Adults Aged 50 Years and O NCT05304351 | Curevo Inc | Phase 2 |
| Completed | Trial to Evaluate the Safety, Tolerability, and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z- NCT05245838 | Dynavax Technologies Corporation | Phase 1 |
| Completed | A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Giv NCT05047770 | GlaxoSmithKline | Phase 3 |
| Completed | Age Differences in Influenza and Herpes Zoster Vaccine Responses (INFLUENZA-SHINGRIX) NCT05082688 | Radboud University Medical Center | Phase 2 |
| Completed | Efficacy, Immunogenicity and Safety Study of GSKs Recombinant Zoster Vaccine Shingrix (GSK1437173A) in Chinese NCT04869982 | GlaxoSmithKline | Phase 4 |
| Unknown | Recombinant Zoster Vaccine in Stable SLE Patients NCT04516408 | RenJi Hospital | N/A |
| Completed | Prospective Observation of the Fluoroscopy-guided Cervical Epidural Approach Using the Contralateral Oblique V NCT04774458 | Asan Medical Center | N/A |
| Completed | The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata NCT04239521 | Momentum Data | — |
| Completed | Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Res NCT04523246 | University of Oklahoma | EARLY_Phase 1 |
| Completed | Persistence of Protection by Shingrix NCT04169009 | University of Colorado, Denver | Phase 4 |
| Completed | A Clinical Trial of PEGIFNα1b in Chinese Healthy Adults NCT05639803 | Shanghai Institute Of Biological Products | Phase 1 |
| Completed | Study on Efficacy of Attenuated Zoster Vaccine, Live NCT04334577 | Changchun BCHT Biotechnology Co. | Phase 3 |
| Unknown | Occlusion vs Standard Treatment for the Treatment of Herpes Zoster NCT04258930 | Fundación Nacional para la Enseñanza y la Investigación de la Dermatología A.C. | N/A |
| Unknown | HIV Indicator Diseases in Hospital and Primary Care NCT05225493 | Erasmus Medical Center | — |
| Completed | A Study to Test GlaxoSmithKline's (GSK) Herpes Zoster (HZ) Subunit Vaccine's Long-term Immune Response in Prev NCT04176939 | GlaxoSmithKline | Phase 3 |
| Recruiting | A Study to Test GlaxoSmithKline's (GSK) Candidate Vaccine-GSK1437173A for Prevention of Shingles in Children W NCT04006808 | GlaxoSmithKline | Phase 1 / Phase 2 |
| Completed | Treatment of Chronic Postherpetic Pain With Autologous Fat Grafting - A RCT NCT04099706 | Odense University Hospital | N/A |
| Completed | Safety and Immunogenicity Study of GlaxoSmithKline's Herpes Zoster Subunit Vaccine (HZ/su) When Given on a Two NCT04091451 | GlaxoSmithKline | Phase 3 |
| Completed | Immunogenicity of Herpes Zoster Subunit Vaccine in Inflammatory Bowel Disease Patients Treated With Vedolizuma NCT03798691 | University of Wisconsin, Madison | Phase 4 |
| Completed | The Superiority of Contralateral Oblique View for Mid-thoracic Epidural Assess NCT03789955 | Asan Medical Center | N/A |
| Completed | Safety, Tolerability, and Immunogenicity of CRV-101 in Healthy Adult Subjects NCT03820414 | Curevo Inc | Phase 1 |
| Completed | Herpes Zoster: Risk Factors, Complications and Special Situations NCT03903237 | University Hospital, Basel, Switzerland | — |
| Completed | A Clinical Study of a Zoster Vaccine in Healthy Adults >= 40 Years NCT04072497 | Shanghai Institute Of Biological Products | Phase 1 / Phase 2 |
| Completed | Efficacy of Pregabalin for the Treatment of Acute Herpetic Neuralgia NCT03809702 | B.P. Koirala Institute of Health Sciences | Phase 4 |
| Completed | A Study to Assess Frailty of Subjects During ZOSTER-006 and ZOSTER-022 NCT03563183 | GlaxoSmithKline | — |
| Completed | Treatment of Chronic Postherpetic Pain With Fat Grafting NCT03584061 | Odense University Hospital | N/A |
| Completed | Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered Wit NCT03439657 | GlaxoSmithKline | Phase 3 |
| Completed | Identifying Young Inflammatory Bowel Disease Patients at Risk for Herpes Zoster NCT03553472 | University of Wisconsin, Madison | — |
| Completed | Efficacy Trial of a Vaccine to Prevent Herpes Zoster in Adults Over 40 Years of Age NCT03314103 | Jiangsu Province Centers for Disease Control and Prevention | Phase 3 |
| Completed | Optimal Timing of Zoster Vaccine After Hematopoietic Stem Cell Transplantation NCT03192319 | Seoul National University Hospital | N/A |
| Unknown | Effect of Early Use of Oxycodone During the Acute Phase of Herpes Zoster on Preventing Postherpetic Neuralgia NCT03120962 | Second Affiliated Hospital, School of Medicine, Zhejiang University | N/A |
| Unknown | Tzanck Smear With Methylene Blue Stain for Herpes NCT03178747 | Chulalongkorn University | Phase 3 |
| Completed | Study to Evaluate the Impact of Reactogenicity on Quality of Life (QoL), After Administration of GlaxoSmithKli NCT02979639 | GlaxoSmithKline | Phase 3 |
| Unknown | Safety and Tolerability of Herpes Zoster Vaccine Rheumatologic Patients NCT03016884 | HaEmek Medical Center, Israel | Phase 4 |
| Completed | Tele-dermatology of Skin Cancer in a Cohort of Local Health Authority Employees in the Province of Bergamo NCT02902822 | Centro Studi Gised | N/A |
| Completed | A Long-term Follow-up Study (ZOE-LTFU) of Two Studies 110390 (ZOSTER-006) and 113077 (ZOSTER-022) to Assess th NCT02723773 | GlaxoSmithKline | Phase 3 |
| Completed | Study to Evaluate Immunogenicity and Safety of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine at 9 and NCT02735915 | GlaxoSmithKline | Phase 3 |
| Completed | Cross-vaccination Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK 1437173A) in Subjects W NCT02690207 | GlaxoSmithKline | Phase 3 |
| Completed | Burden of Herpes Zoster and Post-herpetic Neuralgia Among People ≥ 50 Years Old in France NCT02487472 | GlaxoSmithKline | — |
| Completed | Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (G NCT02581410 | GlaxoSmithKline | Phase 3 |
| Completed | Safety and Immunogenicity Study of Live Attenuated Vaccine Against Herpes Zoster in Chinese Adults Aged 50 Yea NCT02526745 | Beijing Chaoyang District Centre for Disease Control and Prevention | Phase 1 / Phase 2 |
| Completed | Enhancing a Sustainable Pharmacy-based Immunization Program in Two States NCT02615470 | Auburn University | N/A |
| Completed | Postherpetic Neuralgia After Herpes Zoster and Incident Dementia Risk NCT07399288 | China Medical University Hospital | — |
| Completed | Study to Evaluate Immunogenicity, Safety, and Tolerability of ZOSTAVAX™ Vaccine (Zoster Vaccine Live, V211) Ad NCT02519855 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Immunogenicity and Safety of NBP608 Compared to Zostavax in Healthy Adult Aged 50 and Over NCT03120364 | SK Chemicals Co., Ltd. | Phase 3 |
| Terminated | A Comparative Study of FV-100 vs. Valacyclovir for the Prevention of Post-Herpetic Neuralgia NCT02412917 | ContraVir Pharmaceuticals, Inc. | Phase 3 |
| Completed | Herpes Zoster Prevalence in Frailty Consultations NCT02832986 | University Hospital, Toulouse | — |
| Completed | Consistency, Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine NCT02075515 | GlaxoSmithKline | Phase 3 |
| Withdrawn | A Lot-to-Lot Consistency Study to Evaluate Safety, Tolerability, and Immunogenicity of Inactivated Varicella Z NCT02180295 | Merck Sharp & Dohme LLC | Phase 3 |
| Active Not Recruiting | The Immunogenicity and Safety of Zostavax® and Shingrix® in Rheumatoid Arthritis Patients Using Abatacept NCT03604406 | Kevin Winthrop | Phase 2 |
| Completed | Comparison of a Live Herpes Zoster Vaccine and a Recombinant Vaccine in 50-59 and 70-85 Year Olds NCT02114333 | University of Colorado, Denver | Phase 1 |
| Completed | Efficacy and Safety of Foscarnet Sodium and Sodium Chloride Injection in Patients With Herpes Zoster NCT02151240 | Cttq | Phase 4 |
| Completed | Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adult NCT02058589 | GlaxoSmithKline | Phase 3 |
| Completed | Study to Evaluate Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A W NCT02045836 | GlaxoSmithKline | Phase 3 |
| Completed | Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/ NCT02052596 | GlaxoSmithKline | Phase 3 |
| Completed | Immunogenicity and Safety of Two Lots of NBP608 Compared to Zostavax in Healthy Adult Aged 50 and Over NCT03116594 | SK Chemicals Co., Ltd. | Phase 2 / Phase 3 |
| Completed | Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GS NCT01954251 | GlaxoSmithKline | Phase 3 |
| Completed | Phase III Study of ASP2151 in Herpes Zoster Patients NCT01959841 | Maruho Co., Ltd. | Phase 3 |
| Completed | A Study to Assess the Burden of Herpes Zoster and Postherpetic Neuralgia in Japanese Adults Aged Sixty Years a NCT01873365 | GlaxoSmithKline | — |
| Completed | Safety and Immunogenicity Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A When Adm NCT01777321 | GlaxoSmithKline | Phase 3 |
| Completed | Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine GSK14371 NCT01827839 | GlaxoSmithKline | Phase 3 |
| Completed | Placebo Controlled Evaluation of the Cell Mediated Immune Response of Cirrhotic Subjects to Zostavax™ NCT02958345 | Tulane University | Phase 4 |
| Completed | Safety and Immunogenicity of Different Dosing Schedules of GlaxoSmithkline (GSK) Biologicals' Herpes Zoster (H NCT01751165 | GlaxoSmithKline | Phase 3 |
| Completed | Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ/su) Vaccine in Adults NCT01798056 | GlaxoSmithKline | Phase 3 |
| Completed | Study to Assess the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/ NCT01767467 | GlaxoSmithKline | Phase 3 |
| Completed | Study to Estimate the Burden of Herpes Zoster (HZ) and Post-herpetic Neuralgia (PHN) in Italy NCT01772160 | GlaxoSmithKline | — |
| Completed | Safety, Tolerability, and Immunogenicity of Zoster Vaccine Live (ZOSTAVAX™) in Healthy Adults in India (V211-0 NCT01527370 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vac NCT01610414 | GlaxoSmithKline | Phase 3 |
| Completed | Efficacy of Oral Famciclovir Versus Aciclovir Treatment in Patients With Herpes Zoster NCT01327144 | EMS | Phase 3 |
| Completed | ZOSTAVAX™ (Zoster Vaccine Live) Long-term Effectiveness Study (V211-024) NCT01600079 | Merck Sharp & Dohme LLC | — |
| Completed | Herpes Zoster Vaccine for Bone Marrow Transplant Donors NCT01573182 | University of Sydney | Phase 2 |
| Completed | Safety and Immunogenicity of Zoster Vaccine (ZOSTAVAX™) Made With an Alternative Manufacturing Process (AMP) ( NCT01505647 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | ZOSTAVAX™ Safety and Immunogenicity in Korean Adults (V211-034) NCT01556451 | Merck Sharp & Dohme LLC | Phase 4 |
| Completed | Study to Estimate the Burden of Herpes Zoster and Postherpetic Neuralgia in Spain NCT01521286 | GlaxoSmithKline | — |
| Completed | A Study to Evaluate the Safety and Immunogenicity of Inactivated Varicella Zoster Virus (VZV) Vaccine in Adult NCT01527383 | Merck Sharp & Dohme LLC | Phase 2 |
| Completed | A Study to Evaluate the Safety and Immunogenicity of Inactivated Varicella-Zoster Virus (VZV) Vaccine in Adult NCT01460719 | Merck Sharp & Dohme LLC | Phase 1 |
| Unknown | Distances From Cricoid Cartilage to the Targets of Stellate Ganglion Block NCT01601925 | Yonsei University | N/A |
| Completed | Increasing Use of the Vaccine Against Herpes Zoster/Shingles at NYULMC and Bellevue Hospital NCT01483378 | NYU Langone Health | N/A |
| Completed | A Study of Intradermal Administration of ZOSTAVAX™ (V211-051 AM2) NCT01385566 | Merck Sharp & Dohme LLC | Phase 1 |
| Completed | A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Tr NCT01254630 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Immunogenicity and Safety Study of ZOSTAVAX Administered by Intramuscular or Subcutaneous Route to Participant NCT01391546 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | A Study of Vacyless® Versus Valtrex® in Patients With Herpes Zoster NCT02152800 | Yung Shin Pharm. Ind. Co., Ltd. | Phase 4 |
| Completed | Safety, Tolerability, and Immunogenicity of a Booster Dose of Zoster Vaccine, Live (V211-029) NCT01245751 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Study of Long Term Immune Responses and Safety of the GSK Herpes Zoster Vaccine in Healthy Subjects NCT01295320 | GlaxoSmithKline | Phase 2 |
| Withdrawn | Prevention of Varicella Zoster Virus (VZV)-Reactivation in HIV-positive Individuals Enrolled in a Prospective NCT01213810 | University of Zurich | Phase 1 / Phase 2 |
| Completed | A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Tr NCT01229267 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Study to Evaluate GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Human Immunodeficiency Virus (HIV)-Inf NCT01165203 | GlaxoSmithKline | Phase 2 |
| Completed | ZOSTAVAX® in Renal Transplant Patients NCT01137669 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | T Cell Responses to Varicella Zoster Virus (VZV) Vaccine SLVP020 NCT01911065 | Stanford University | Phase 4 |
| Completed | Study to Evaluate Efficacy, Safety and Immunogenicity of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK143717 NCT01165177 | GlaxoSmithKline | Phase 3 |
| Completed | Study to Evaluate Efficacy, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) NCT01165229 | GlaxoSmithKline | Phase 3 |
| Unknown | Development of a Bedside Pain Assessment Kit for Postherpetic Neuralgia NCT01166295 | Analgesic Solutions | — |
| Completed | Safety and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine 1437173A in Healthy Ethnic Japanese Adults NCT01086449 | GlaxoSmithKline | Phase 1 |
| Completed | Safety & Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A NCT00920218 | GlaxoSmithKline | Phase 2 |
| Completed | Immune Response to Varicella-Zoster Vaccination and Infection NCT00921999 | National Institute of Allergy and Infectious Diseases (NIAID) | — |
| Completed | A Study of FV-100 Versus Valacyclovir in Patients With Herpes Zoster NCT00900783 | Bristol-Myers Squibb | Phase 2 |
| Completed | Live Zoster Vaccine in HIV-Infected Adults on Antiretroviral Therapy NCT00851786 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Completed | Intravenous Vitamin C in the Treatment of Viral Infection, Especially in the Treatment of Shingles NCT00921934 | Pascoe Pharmazeutische Praeparate GmbH | — |
| Completed | A Study to Evaluate Immunity to Varicella Zoster Virus After Immunization With V212 Vaccine or Zostavax (V212- NCT00886613 | Merck Sharp & Dohme LLC | Phase 1 |
| Completed | Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine With Various Formulations in Adults NCT00802464 | GlaxoSmithKline | Phase 2 |
| Completed | A Study to Test the Safety and Antibody Response of V212 in Healthy Adults (V212-004)(COMPLETED) NCT00696709 | Merck Sharp & Dohme LLC | Phase 1 |
| Completed | Acupuncture in Herpes Zoster Neuralgia (ACUZoster) NCT00885586 | Dominik Irnich | Phase 4 |
| Completed | Zostavax® at Minimum Release Specification Approaching Expiry (V211-044) NCT00681031 | Merck Sharp & Dohme LLC | Phase 4 |
| Unknown | Study to Compare Efficacy of Topical ARYS-01 (Sorivudine) Cream 3%, Oral Valaciclovir and Combination ARYS-01 NCT00652184 | aRigen Pharmaceuticals, Inc. | Phase 2 |
| Completed | The Effect of Pharmacist Intervention on the Use of Zostavax in a Community Pharmacy Setting NCT00689013 | University of Tennessee | N/A |
| Completed | Activation of Alternative Cellular Energy (ACE) Pathway in the Therapy of Herpes Virus Infections NCT00642785 | Institute of Progressive Medicine | — |
| Completed | Dose-finding Study of ASP2151 in Subjects With Herpes Zoster NCT00487682 | Astellas Pharma Inc | Phase 2 |
| Completed | A Study of an Investigational V212/Heat-Treated Varicella-Zoster Virus (VZV) Vaccine in Immunocompromised Adul NCT00535236 | Merck Sharp & Dohme LLC | Phase 1 |
| Completed | A 2 Week Study of Topical KD7040 in the Treatment of Postherpetic Neuralgia (PHN) NCT00576108 | Kalypsys, Inc. | Phase 2 |
| Completed | A Phase 2b Trial of EPB-348 for the Treatment of Herpes Zoster NCT00831103 | Epiphany Biosciences | Phase 2 |
| Completed | ZOSTAVAX™ in Patients on Chronic/Maintenance Corticosteroids (V211-017) (COMPLETED) NCT00546819 | Merck Sharp & Dohme LLC | Phase 2 |
| Completed | ZOSTAVAX™ Safety Study in Subjects ≥ 60 Years of Age (V211-020) NCT00550745 | Merck Sharp & Dohme LLC | Phase 4 |
| Completed | VZV PCR Sampling Validation Study NCT00501670 | GlaxoSmithKline | — |
| Completed | Month 30 & 42 Extension Studies of CRD-004 Primary Study NCT00492648 | GlaxoSmithKline | Phase 2 |
| Completed | ZOSTAVAX™ Administered Concomitantly With PNEUMOVAX™ 23 (V211-012)(COMPLETED) NCT00535730 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Measuring Herpes Zoster and PHN Associated Burden of Illness and Health Care Utilization Costs in Thailand NCT00526864 | Mahidol University | — |
| Completed | An Effectiveness and Safety Study With RWJ-333369 (Carisbamate) for the Study of Postherpetic Neuralgia (PHN). NCT00492323 | SK Life Science, Inc. | Phase 2 |
| Completed | Safety and Immunogenicity of the Zoster Vaccine GSK1437173A in Elderly Subjects NCT00434577 | GlaxoSmithKline | Phase 2 |
| Completed | Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fasting Conditions NCT01132729 | Roxane Laboratories | N/A |
| Completed | Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fed Conditions NCT01132716 | Roxane Laboratories | N/A |
| Terminated | Study to Find Out if Therapy With the Drug Pregabalin Relieves Pain During Shingles Compared With Placebo NCT00352651 | University of California, San Francisco | Phase 2 |
| Completed | A Study of an Investigational Zoster Vaccine, in Subjects With a History of Herpes Zoster (V211-014) NCT00322231 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Study of NGX-4010 for the Treatment of Postherpetic Neuralgia NCT00300222 | NeurogesX | Phase 3 |
| Completed | A Study of an Investigational Zoster Vaccine in Subjects With a History of Varicella (Chickenpox) Given Concom NCT00231816 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Study to Evaluate the Safety and Pharmacokinetics of Single Doses of ASP2151 in Healthy Male Subjects and the NCT02852876 | Astellas Pharma Europe Ltd. | Phase 1 |
| Completed | A Study to Evaluate Safety, Tolerability, and Immunogenicity of an Investigational Zoster Vaccine In Subjects NCT00130793 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Study of NGX-4010 for the Treatment of Painful HIV-Associated Neuropathy (HIV-AN) or Postherpetic Neuralgia (P NCT00233155 | NeurogesX | Phase 2 |
| Completed | Famciclovir Oral Pediatric Formulation in Children 1-12 Years of Age With Varicella Zoster Infection NCT00098046 | Novartis | Phase 3 |
| Completed | Study of NGX-4010 for the Treatment of Postherpetic Neuralgia NCT00115310 | NeurogesX | Phase 3 |
| Completed | Pilot Study of High-Dose Capsaicin Patches to Treat Postherpetic Neuralgia Pain NCT00034710 | NeurogesX | Phase 2 |
| Completed | Reduction of Postherpetic Neuralgia in Herpes Zoster NCT01250561 | Center for Clinical Studies, Texas | N/A |
| Completed | Shingles: Immune Effects of Tai Chi NCT00118885 | National Institute on Aging (NIA) | Phase 2 |
| Completed | Shingles Prevention Study NCT00007501 | US Department of Veterans Affairs | Phase 3 |
| Completed | Randomized Study of Two Doses of Oral Valacyclovir in Immunocompromised Patients With Uncomplicated Herpes Zos NCT00006131 | National Center for Research Resources (NCRR) | N/A |
| Completed | A Study to Evaluate Long-term Impact of VARIVAX Among Children and Adolescents (V210-036)(COMPLETED) NCT01077804 | Merck Sharp & Dohme LLC | — |
| Completed | Phase III Randomized Controlled Study of Morphine and Nortriptyline in the Management of Postherpetic Neuralgi NCT00004390 | National Center for Research Resources (NCRR) | Phase 3 |
| Completed | Dextromethorphan Versus Placebo for Neuropathic Pain NCT00001344 | National Institute of Dental and Craniofacial Research (NIDCR) | Phase 2 |
| Completed | Controlled Study of NGX-4010 for the Treatment of Postherpetic Neuralgia NCT00068081 | NeurogesX | Phase 3 |
| Completed | Tolerability of Three Local Anesthetic Formulations in Conjunction With NGX-4010 for the Treatment of Neuropat NCT00082316 | NeurogesX | Phase 2 |
| Completed | NGX-4010 for the Treatment of Postherpetic Neuralgia NCT00061776 | NeurogesX | Phase 2 / Phase 3 |
| Terminated | An Open-Label Extension Study of NGX-4010 for the Treatment of Neuropathic Pain NCT00089557 | NeurogesX | Phase 2 |